ERBB2 and breast carcinoma: (Table 3) Prior reports of imaging using SPECT and PET radionuclides chelated to the whole trastuzumab antibody have been performed in HER2(+) breast cancer patients scheduled to receive trastuzumab therapy, typically incorporating a loading dose of “cold” (non-radiolabeled) trastuzumab.